Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as ...

US pharma firms face higher drug costs, delayed launches, and compliance risks from proposed sectoral tariffs, prompting ...

Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999.

In this exclusive Drug Digest video, Deepak Bahl from Roquette and Jagruti Patel from Lonza look at strategies for ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

US pharma tariffs may start low and rise, risking drug shortages, higher costs, and pressure on generics amid reshoring push.